@entity1024 receptors (NRs) are a group of ionotropic @entity2227 receptors in the brain and they are composed of heteromeric subunits ( @entity4474 , @entity4476 -D and @entity26305 ). In the neostriatum, a brain region that is associated with movement in animals, @entity143 channels are known to involve in the motor control. Our previous report (Lai et al., 2000, Neuroscience 98, 493-500) has shown that a single dose of antisense oligodeoxynucleotides that are specific to @entity4474 subunit results in blockage of the gene expression of @entity4474 as well as @entity4476 subunits in the neostriatum. In the present study, antisense oligodeoxynucleotides that are specific to @entity4319 (ANR2B) were then employed as molecular tools to further investigate the molecular interactions of @entity143 receptor subunits in the neostriatum. A single dose of ANR2B was injected unilaterally into the @entity35 neostriatum. After one day of injection, no modification of motor behavior was found in the ANR2B-injected @entity35 . The mRNA level of @entity4319 in the ANR2B-injected neostriatum was found to be decreased (-20.4%) by reverse transcriptase polymerase chain reaction (RT-PCR). However, the mRNA levels of @entity4474 , @entity4476 , @entity4477 and @entity4475 in the ANR2B-treated neostriatum were found to be unchanged. After two days of injection, @entity4319 immunoreactivity was found to decrease in the ANR2B-treated neostriatum by immunofluorescence (-35.1%). At higher magnification, @entity4319 immunoreactivity was found to decrease in presumed spiny neurons of the neostriatum (-23.4%). No change in @entity4474 immunoreactivity was observed. These results indicate that a single dose of ANR2B can successfully block the gene expression of @entity4319 in neurons of the neostriatum and there is less effect on @entity4474 and other NR2 subunits. The blockage of the gene expression of @entity4319 is therefore specific and the present results may provide important implications in applications of antisense in research and in clinical therapy of @entity16 .

Modulation of the gene expression of @entity1024 receptor @entity4319 subunit in the XXXX neostriatum by a single dose of specific antisense oligodeoxynucleotide.

@entity26305 :: ('191573(Tax:10116)', 'Gene') :: ['NR3'] @entity4477 :: ('24411(Tax:10116)', 'Gene') :: ['NR2C'] @entity1024 :: ('CHEBI:31882', 'Chemical') :: ['N-methyl-D-aspartate'] @entity2227 :: ('CHEBI:29987', 'Chemical') :: ['glutamate'] @entity4319 :: ('24410(Tax:10116)', 'Gene') :: ['NR2B'] @entity4475 :: ('24412(Tax:10116)', 'Gene') :: ['NR2D'] @entity4476 :: ('24409(Tax:10116)', 'Gene') :: ['NR2A'] @entity16 :: ('MESH:D009422', 'Disease') :: ['neurological diseases'] @entity4474 :: ('24408(Tax:10116)', 'Gene') :: ['NR1'] @entity143 :: ('CHEBI:6121', 'Chemical') :: ['NMDA'] @entity35 :: ('10116', 'Species') :: ['rat', 'rats']
@entity35 :: (10116,Species) :: ['rat']
